Preview Mode Links will not work in preview mode

GetBriefed Australia Podcast

Nov 4, 2020

Dr Tom Dover explains the new indication for dulaglutide (adjunct to standard of care to reduce the risk of MACE in T2D patients with established CVD OR multiple CVD risk factors) in the context of recent Australian and international guideline recommendations to consider CVD risk when selecting glucose lowering therapies. Practical implications for Australian GPs are discussed.